Angiotensin Converting Enzyme 2 News and Research

RSS

Eli Lilly's LY-CoV555 antibody shows potential as COVID-19 treatment

Researchers in the United States and Canada have discovered a monoclonal antibody that potently neutralizes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

5 Oct 2020

Study confirms SARS-CoV-2 spike glycoprotein promotes a hyper-inflammatory immune response

A group of researchers from Australia and China recently demonstrated how SARS-CoV-2 spike glycoprotein subunit 1 can induce a pro-inflammatory signaling pathway (leading to cytokines deployment and epithelial damage in human bronchial epithelial cells), but also highlighted the potential of peptide-based antivirals in tackling this novel coronavirus.

5 Oct 2020

Macrophage subgroups may play pivotal role in COVID-19 lethality

Many researchers are attempting to identify risk factors for severe or critical COVID-19. A recent paper in the journal Medical Hypotheses in September 2020 suggests that macrophage class activation is one of the factors that determine the clinical phenotype of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

5 Oct 2020

Advanced model reveals dynamic motions of SARS-COV-2 spike-shielding glycans

A recent paper published on the preprint server bioRxiv in September 2020 discusses the dynamic interactions of the spike protein glycan shield, which may be of great value in developing therapeutic compounds to fight severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Oct 2020

Sebum changes in COVID-19 patients, for future testing and prognosis

Now, a new study published on the preprint server medRxiv in September 2020 shows that sebum lipids change in COVID-19. This could help develop a cheap and straightforward method of non-invasive diagnosis.

5 Oct 2020

Furin cleavage site of SARS-CoV-2 spike glycoprotein enhances viral replication in the lungs

In a new bioRxiv* preprint paper, researchers from the Imperial College London, King's College London, and the University of Bristol in the United Kingdom show that the furin cleavage site of SARS-CoV-2 spike glycoprotein represents a key determinant for transmission among humans, as it substantially facilitates replication in airway cells - opening the door for the development of novel therapeutics.

4 Oct 2020

Lung tissue in fatal COVID-19 shows broad cell tropism and extensive damage

In a recent preprint paper published on the medRxiv server, researchers demonstrated their investigation of fatal COVID-19 patients to assess infection in various cell types and the extent of damage it caused to the lung tissues.

30 Sep 2020

Maternal immune cells could bring SARS-CoV-2 to the placenta

Researchers from Canada and Brazil collaborated to explore the possibility of perinatal transmission of the virus from pregnant mothers to their babies and the risk of preterm birth.

30 Sep 2020

Discovery of high affinity binders for SARS-CoV-2 spike protein

An exciting, 'tour-de-force' paper by researchers from the Massachusetts Institute of Technology describes de novo discovery of high-affinity peptide binders for SARS-CoV-2 spike glycoprotein, which opens the door for the development of rapid viral identification or conjugates for virus-directed delivery of therapeutics.

30 Sep 2020

SARS-CoV-2 D614G variant enhances infectivity, replication and transmission

Researchers in the United States and Japan have conducted a study showing a common mutation in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the agent that causes coronavirus disease 2019 (COVD-19) - enhances the infectivity, replication, and early transmission of the virus.

30 Sep 2020

Newly developed fusion protein could improve COVID-19 research

Researchers at the Paul Scherrer Institute in Switzerland have developed a high-quality recombinant virus protein that could be applied in the development of vaccines against the 2019 novel coronavirus (2019-nCoV) and in the detection of novel viruses or antibodies.

30 Sep 2020

A TLR2 agonist reduces SARS-CoV-2 in upper respiratory tract of ferret model

In a recent bioRxiv* preprint paper, Professor Miles W. Carroll et al. study an agonist for reducing the SARS-CoV-2's viral load. They show that prophylactic intra-nasal administration of TLR2/6 (toll-like receptor) agonist, INNA-051, reduces viral RNA in the nose and throat, in a ferret model.

30 Sep 2020

SARS-CoV-2 infects human embryonic epithelial and lung cells

As COVID-19 continues to spread the world over, investigators are still trying to understand how it ravages the human body. A recent study published on the preprint server bioRxiv in September 2020 shows that the virus is capable of infecting human embryonic cells that are destined to form the epithelial surfaces of the body, both internal and external, as well as lung cells.

29 Sep 2020

Healthy vitamin D levels could reduce COVID-19 complications

Published in the journal PLOS ONE, the study investigates the link between serum 25-hydroxyvitamin D levels and its effect on adverse clinical outcomes and parameters of immune function and mortality due to COVID-19.

28 Sep 2020

COVID-19 may deteriorate men's testosterone levels, new data suggests

For the first time, data from a study with patients hospitalized due to COVID-19 suggest that the disease might deteriorate men's testosterone levels.

28 Sep 2020

Clover Biopharma's new trimeric subunit vaccine candidate prevents COVID-19 in monkeys

The vaccine candidate produced a high level of neutralizing antibodies in animal models. Rhesus macaques immunized with the vaccine candidate showed reduced viral loads in the lungs. The research is published on the preprint server bioRxiv.

28 Sep 2020

Human recombinant soluble ACE2 successfully used in a patient with severe COVID-19

A multinational research group recently published a paper in the journal Lancet Respiratory Medicine which describes the first patient with a severe form of coronavirus disease (COVID-19) that was successfully treated with human recombinant soluble ACE2.

27 Sep 2020

Researchers compare the effect of two anti-hypertensive drugs on post-exercise hypotension

Researchers in the University of São Paulo's School of Physical Education and Sports (EEFE-USP) in Brazil compared the effect of two widely used classes of anti-hypertensive drugs on post-exercise hypotension, an expected and beneficial fall in blood pressure after a session of aerobic exercise, especially in the late afternoon or early evening.

25 Sep 2020

Linoleic acid binds SARS-CoV-2 spike protein

Now, a team of researchers at the Max Planck-Bristol Center for Minimal Biology and Bristol's School of Biochemistry has identified a druggable pocket in the virus's spike protein that can be used to prevent the infection of cells. The study findings, published in the journal Science, are a groundbreaking discovery that will help develop new therapies and drugs to stem the growing pandemic.

24 Sep 2020

Prevalence of SARS-CoV-2 with D614G mutation in a second wave infection in Houston

A recent study reveals that the genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detected in the initial phase of coronavirus disease 2019 (COVID-19) pandemic differ from the variants detected in a massive second wave of infection in Houston, Texas. The study is currently available on the medRxiv preprint server.

24 Sep 2020